Pharmacyclics (PCYC +10.2%) continues its climb again today on the back of the FDA's orphan status approval of its chronic lymphocyctic leukemia treatment. Analysts are projecting blockbuster sales for the cancer drug, including Brean Murray, who initiated the shares with a Buy earlier today on the back of the announcement.
Pharmacyclics (PCYC +10.2%) continues its climb again today on the back of the FDA's orphan...
From other sites
at CNBC.com (Jan 13, 2015)
at CNBC.com (Dec 5, 2014)
at CNBC.com (Sep 17, 2014)
at CNBC.com (Jul 29, 2014)
at CNBC.com (Jul 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs